DESIGN AND ANALYSIS OF CLINICAL TRIALS

Concepts and Methodologies

Second Edition

SHEIN-CHUNG CHOW
Millennium Pharmaceuticals, Inc.
Cambridge, MA

JEN-PEI LIU
National Cheng-kung University
Tainan, Taiwan
National Health Research Institutes
Taipei, Taiwan

 Wiley-Interscience
A John Wiley & Sons, Inc., Publication
CONTENTS

Preface ix
Preface to the First Edition xi

1. Introduction 1
   1.1 What are Clinical Trials?, 1
   1.2 History of Clinical Trials, 3
   1.3 Regulatory Process and Requirements, 7
   1.4 Investigational New Drug Application, 15
   1.5 New Drug Application, 22
   1.6 Clinical Development and Practice, 31
   1.7 Aims and Structure of the Book, 35

2. Basic Statistical Concepts 43
   2.1 Introduction, 43
   2.2 Uncertainty and Probability, 44
   2.3 Bias and Variability, 47
   2.4 Confounding and Interaction, 55
   2.5 Descriptive and Inferential Statistics, 65
   2.6 Hypothesis Testing and \( p \)-Values, 71
   2.7 Clinical Significance and Clinical Equivalence, 77
   2.8 Reproducibility and Generalizability, 82

3. Basic Design Considerations 88
   3.1 Introduction, 88
   3.2 Goals of Clinical Trials, 89
3.3 Target Population and Patient Selection, 93
3.4 Selection of Controls, 100
3.5 Statistical Considerations, 109
3.6 Other Issues, 116
3.7 Discussion, 118

4. Randomization and Blinding 120
   4.1 Introduction, 120
   4.2 Randomization Models, 122
   4.3 Randomization Methods, 127
   4.4 Implementation of Randomization, 149
   4.5 Generalization of Controlled Randomized Trials, 154
   4.6 Blinding, 158
   4.7 Discussion, 165

5. Designs for Clinical Trials 167
   5.1 Introduction, 167
   5.2 Parallel Group Designs, 169
   5.3 Cluster Randomized Designs, 174
   5.4 Crossover Designs, 179
   5.5 Titration Designs, 188
   5.6 Enrichment Designs, 194
   5.7 Group Sequential Designs, 200
   5.8 Placebo-Challenging Design, 202
   5.9 Blinded Reader Designs, 208
   5.10 Discussion, 212

6. Designs for Cancer Clinical Trials 215
   6.1 Introduction, 215
   6.2 General Considerations for Phase I Cancer Clinical Trials, 217
   6.3 Single-Stage Up-and-Down Phase I Designs, 218
   6.4 Two-Stage Up-and-Down Phase I Designs, 220
   6.5 Continual Reassessment Method Phase I Designs, 223
   6.6 Optimal/Flexible Multiple-Stage Designs, 226
   6.7 Randomized Phase II Designs, 232
   6.8 Discussion, 236

7. Classification of Clinical Trials 239
   7.1 Introduction, 239
   7.2 Multicenter Trial, 240
   7.3 Superiority Trials, 247
   7.4 Active Control and Equivalence/Noninferiority Trials, 250
   7.5 Dose-Response Trials, 265
   7.6 Combination Trials, 270
   7.7 Bridging Studies, 283
   7.8 Vaccine Clinical Trials, 289
   7.9 Discussion, 296
8. Analysis of Continuous Data 300

8.1 Introduction, 300
8.2 Estimation, 301
8.3 Test Statistics, 305
8.4 Analysis of Variance, 311
8.5 Analysis of Covariance, 316
8.6 Nonparametrics, 320
8.7 Repeated Measures, 326
8.8 Discussion, 337

9. Analysis of Categorical Data 339

9.1 Introduction, 339
9.2 Statistical Inference for One Sample, 344
9.3 Inference of Independent Samples, 356
9.4 Ordered Categorical Data, 362
9.5 Combining Categorical Data, 366
9.6 Model-Based Methods, 372
9.7 Repeated Categorical Data, 379
9.8 Discussion, 384

10. Censored Data and Interim Analysis 386

10.1 Introduction, 386
10.2 Estimation of the Survival Function, 388
10.3 Comparison between Survival Functions, 394
10.4 Cox’s Proportional Hazard Model, 402
10.5 Calendar Time and Information Time, 417
10.6 Group Sequential Methods, 422
10.7 Discussion, 435

11. Sample Size Determination 438

11.1 Introduction, 438
11.2 Basic Concept, 439
11.3 Two Samples, 443
11.4 Multiple Samples, 452
11.5 Censored Data, 464
11.6 Dose-Response Studies, 468
11.7 Crossover Designs, 474
11.8 Equivalence and Noninferiority Trials, 481
11.9 Multiple-Stage Design in Cancer Trials, 492
11.10 Comparing Variabilities, 493
11.11 Discussion, 508

12. Issues in Efficacy Evaluation 510

12.1 Introduction, 510
12.2 Baseline Comparison, 512